



Express Mail No. : EV 475 141 158 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jin et al.

Confirmation No.: 8169

Serial No.: 09/724,388

Art Unit: 1648

Filed: November 28, 2000

Examiner: Lucas, Zachariah

For: RECOMBINANT RSV EXPRESSION  
SYSTEMS AND VACCINES

Attorney Docket No: 7682-051-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97 & §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 15, 2004 and in accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references **DK-DO** listed on the attached revised PTO-1449 Form entitled "List of References Cited by Applicant." Legible copies of references **DK-DO** are enclosed.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

10/20/2004 EFLORES 00000167 503013 09724388

01 FC:1806 180.00 DA

Pursuant to 37 C.F.R. § 1.97(c)(2), since this Information Disclosure Statement is being filed before the mailing date of a final Office Action, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$180.00. Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted, *by: Jacqueline Benn*  
*Ref No 43,492*

Date: October 15, 2004

*Laura A. Coruzzi* 30,742  
Laura A. Coruzzi (Reg. No.)  
JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6702  
(212) 586-3939

Express Mail No. : EV 475 141 158 US

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO. <b>7682-051-999</b>	APPLICATION NO <b>09/724,388</b>
	APPLICANT <b>Jin et al.</b>	
	FILING DATE <b>November 28, 2000</b>	GROUP <b>1648</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	DK	WO 96/40945	12/19/96	PCT				

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	DL	Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. 1998 Jul;11(3):430-439
	DM	Crowe et al. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine. 1994 Jul;12(9):783-790
	DN	Prince et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol. 2000 Nov;74(22):10287-10292
	DO	Tang et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol. 2003 Oct;77(20):10819-10828

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.